drugset
drugset / Trial / NCT00742105

Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan

NCT00742105 ↗

Phase 1 Terminated 18 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will confirm safety and tolerability and determine the MTD of BGT226 in Japanese patients with advanced solid tumor.

Timeline

Start
2008-11-17
Primary completion
2009-12-22
Completion
2009-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject BGT226 Small molecule — Oral

Indications

cancer